Summit Global Investments

Position in NBIX — Neurocrine Biosciences Inc

CIK 1697953 BOUNTIFUL, UT

Position in NBIX

as of Mar 31, 2026 · filed May 7, 2026 Compact

Position Value

$2,250,514

-$1,267,437 QoQ

Shares Held

17,083

-31.1% QoQ

Ownership

0.017%

of shares outstanding

% of Portfolio

0.36%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

15 quarters on record

Healthcare · as of Mar 31, 2026

Summit Global Investments holds $9,305,086 across 6 Drug Manufacturers - Specialty & Generic names. NBIX ranks #2 (24.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	UTHR	UNITED THERAPEUTICS Corp	5,917	$3,508,662
2	NBIX	Neurocrine Biosciences Inc This page	17,083	$2,250,514
3	TAK	Takeda Pharmaceutical Co Ltd	116,494	$2,157,468
4	RDY	Dr Reddys Laboratories Ltd	53,845	$745,753
5	ALKS	Alkermes plc.	11,691	$413,393
6	SUPN	Supernus Pharmaceuticals, Inc.	4,436	$229,296

15 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,250,514	17,083	-31.1%	Shares	Sole	2026-05-07
2025-12-31	$3,517,951	24,804	-31.4%	Shares	Sole	2026-02-18
2025-09-30	$5,075,438	36,155	+214.0%	Shares	Sole	2025-11-03
2025-06-30	$1,447,446	11,516	+5.9%	Shares	Sole	2025-08-12
2025-03-31	$1,203,106	10,878	-66.1%	Shares	Sole	2025-04-07
2024-12-31	$4,376,190	32,060	-40.2%	Shares	Sole	2025-02-11
2024-09-30	$6,173,141	53,577	-31.0%	Shares	Sole	2024-10-31
2024-06-30	$10,683,329	77,601	+56.8%	Shares	Sole	2024-07-22
2024-03-31	$6,823,867	49,477	+21.5%	Shares	Sole	2024-04-29
2023-12-31	$5,366,980	40,733	+35.6%	Shares	Sole	2024-02-06
2023-09-30	$3,379,162	30,037	+1.4%	Shares	Sole	2023-10-16
2023-06-30	$2,794,203	29,631	+2.2%	Shares	Sole	2023-07-19
2023-03-31	$2,933,861	28,985	+8.7%	Shares	Sole	2023-05-04
2022-12-31	$3,186,181	26,676	+128.1%	Shares	Sole	2023-01-31
2022-09-30	$1,242,338	11,697	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.